SAN DIEGO--(BUSINESS WIRE)--Goldman Sachs (NYSE:GS) is recognizing Rahul Singhvi, ScD, Chief Executive Officer of National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, as one of the Most Exceptional Entrepreneurs of 2022 at its Builders and Innovators Summit in Healdsburg, California.
Goldman Sachs selected Dr. Singhvi from multiple industries to be honored at the two-day event. As a recognized global life sciences industry leader, Dr. Singhvi has served as Chief Executive Officer of Resilience since the company’s founding in 2020 to both democratize patient access to complex medicines by continuously advancing science and technology in biopharmaceutical manufacturing and to protect the healthcare industry from potential future supply chain disruptions.
“I am honored to be recognized with this award which wouldn’t have been possible without the incredible efforts made by the entire Resilience team toward meaningful innovations in biomanufacturing,” said Rahul Singhvi, ScD, Chief Executive Officer. “As we continue to establish our manufacturing network across North America, our goal is to help more people that could benefit from lifesaving medicines.”
“We’re delighted to recognize Rahul Singhvi as one of the most exceptional entrepreneurs of 2022,” said David M. Solomon, Chairman and CEO of Goldman Sachs. “This year’s recipients have made extraordinary contributions to a wide range of fields, and all of us are looking forward to meeting with these innovative thinkers.”
In addition to honoring the most exceptional entrepreneurs, the Summit includes general sessions and clinics led by veteran entrepreneurs, members of academia and business leaders as well as resident scholars.
About Resilience
Resilience is a technology-focused biomanufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a sustainable network of high-tech, end-to-end manufacturing solutions to ensure the treatments of today and tomorrow can be made quickly, safely, and at scale. Resilience seeks to free its partners to focus on the discoveries that improve patients’ lives by continuously advancing the science of biopharmaceutical manufacturing and development. For more information, visit www.Resilience.com and follow us on social media: @IncResilience on Twitter and Resilience on LinkedIn.
